Product Overview

Co-capping T7 in vitro transcription reagent is a co-transcription capping reagent for in vitro transcription of 5'capped mRNA to produce Cap-1 structure with an optimized RNA synthesis formulation.

The kit is capable of synthesizing mRNAs that contain a natural Cap-1 structure in a single simplified reaction without compromising RNA yield using linear double-stranded DNA containing T7 promoter followed by an AG initiation sequence.

The kit contains modified nucleotides N1-Me-pUTP as alternative. Capped mRNAs with modified nucleotide have lower immunogenic potential.

Each standard reaction yields up to 150-200 μg of RNA from 1μg DNA template. Reaction size can be scaled up to yield milligram-level RNA as needed.

RNA synthesized from the kit is suitable for many applications including RNA structure and function studies, transfections, microinjections, in vitro translation, preclinical mRNA therapeutic mRNA studies.

Key Features

One-Step Cap-1 mRNA Synthesis

Enables the generation of natural Cap-1 mRNA in a single co-transcriptional reaction, eliminating the need for separate post-transcriptional capping steps and simplifying workflow design.

High Yield Without Compromise

Delivers up to 180-220 μg of capped mRNA from 1 μg of DNA template, maintaining excellent productivity while achieving efficient Cap-1 incorporation.

Compatible with N1-Me-pUTP Incorporation

Supports the incorporation of N1-Me-pUTP during IVT, enabling the production of modified mRNA with reduced innate immunogenic potential.

Enhanced mRNA Quality

The kit utilizes an engineered high-specific-activity T7 RNA Polymerase mutant to minimize transcriptional side reactions and generate transcripts with excellent integrity and reproducibility.

Complete, Ready-to-Use Workflow

Supplied as a fully optimized co-transcriptional capping system containing all essential reagents, eliminating manual formulation and reducing process development time.

Applications

Cap-1 mRNA Therapeutic Development

Designed for the production of natural Cap-1 mRNA for mRNA vaccines, gene therapies, and other RNA-based therapeutics requiring enhanced translational efficiency and improved biological performance.

Modified mRNA Production

Supports the synthesis of N1-Me-pUTP-modified, Cap-1 mRNA, combining co-transcriptional capping with modified nucleotide incorporation in a streamlined workflow.

Preclinical Research and Process Development

Suitable for preclinical mRNA studies, IVT process optimization, and early-stage therapeutic development, enabling rapid access to high-quality capped mRNA.

In Vitro Translation and Cellular Applications

The resulting capped transcripts are suitable for applications including in vitro translation, transfection, microinjection, and RNA functional studies.

Performance Data

Yield Comparison & Integrity Comparison

dsRNA Content Comparison

Performance on Different Length Templates

Component List

FAQ

Can this kit generate Cap-1 mRNA in a single reaction?

Yes. The kit enables the synthesis of natural Cap-1 mRNA through a one-step co-transcriptional capping process, eliminating the need for separate post-transcriptional capping steps.

Is the kit compatible with N1-Me-pUTP incorporation?

Yes. The kit supports the incorporation of N1-Me-pUTP during IVT, enabling the production of modified Cap-1 mRNA with reduced innate immunogenic potential.

Does co-transcriptional capping affect RNA yield?

No. The optimized reaction system is designed to maintain high RNA productivity while achieving efficient Cap-1 incorporation, generating up to 150-200 μg of capped mRNA from 1 μg of DNA template.

Please update this value if the final validated specification is 180-220 μg.

What applications is this kit suitable for?

The kit is suitable for the development of mRNA vaccines, gene therapies, preclinical mRNA studies, in vitro translation, transfection, and other applications requiring natural Cap-1 mRNA.

Does this kit require a specific template design?

Yes. The kit uses linear double-stranded DNA templates containing a T7 promoter followed by an AG initiation sequence to achieve optimal co-transcriptional capping performance.

How should the kit be stored and transported?

The kit should be transported below 0°C and stored at -25 to -15°C to maintain optimal stability and performance.